All In Biotech

Drug Trial Radar · NCT06462118

A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects

A Phase 1, Open-Label, Randomized, Single Dose Study to Evaluate the Effect of Injection Site on the Pharmacokinetics of Astegolimab in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jan 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Jun 17, 2024

Primary completion

Oct 22, 2024

Study completion Oct 22, 2024

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective is to study how astegolimab may behave in the body when injected subcutaneously into the abdomen, thigh, or upper arm in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

  • AstegolimabDrug

    Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the curve from Hour 0 to the time of last measurable concentration (AUC0-t) of astegolimabTime frame: Approximately 85 days
  2. AUC extrapolated to infinity (AUC0-infinity) of astegolimabTime frame: Approximately 85 days
  3. Maximum serum concentration (Cmax) of astegolimabTime frame: Approximately 85 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Covance Research Unit - Daytona

    Daytona Beach, Florida

  • Covance Research Unit - Dallas

    Dallas, Texas

  • Covance Clinical Research Unit, Inc

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.